|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.
|
|
2
|
Ahmad Kiadaliri A, Jarl J, Gavriilidis G
and Gerdtham UG: Alcohol drinking cessation and the risk of
laryngeal and pharyngeal cancers: a systematic review and
meta-analysis. PLoS One. 8:e581582013.
|
|
3
|
Marioni G, Marchese-Ragona R, Cartei G,
Marchese F and Staffieri A: Current opinion in diagnosis and
treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515.
2006.
|
|
4
|
Licitra L, Bernier J, Grandi C, Locati L,
Merlano M, Gatta G and Lefebvre JL: Cancer of the larynx. Crit Rev
Oncol Hematol. 47:65–80. 2003.
|
|
5
|
Pommier Y, Leteurtre F, Fesen MR, Fujimori
A, Bertrand R, Solary E, Kohlhagen G and Kohn KW: Cellular
determinants of sensitivity and resistance to DNA topoisomerase
inhibitors. Cancer Invest. 12:530–542. 1994.
|
|
6
|
Kellner U, Sehested M, Jensen PB, Gieseler
F and Rudolph P: Culprit and victim - DNA topoisomerase II. Lancet
Oncol. 3:235–243. 2002.
|
|
7
|
Nitiss JL: DNA topoisomerase II and its
growing repertoire of biological functions. Nat Rev Cancer.
9:327–337. 2009.
|
|
8
|
Withoff S, de Vries EG, Keith WN, Nienhuis
EF, van der Graaf WT, Uges DR and Mulder NH: Differential
expression of DNA topoisomerase II alpha and -beta in P-gp and
MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the
human SCLC cell line GLC4. Br J Cancer. 74:1869–1876. 1996.
|
|
9
|
Bredel M, Slavc I, Birner P, Czech T,
Haberler C, Ströbel T, Wolfsberger S, Budka H and Hainfellner JA:
DNA topoisomerase IIalpha expression in optic pathway gliomas of
childhood. Eur J Cancer. 38:393–400. 2002.
|
|
10
|
Coleman LW, Bronstein IB and Holden JA:
Immunohistochemical staining for DNA topoisomerase I, DNA
topoisomerase II-alpha and p53 in gastric carcinomas. Anticancer
Res. 21:1167–1172. 2001.
|
|
11
|
Monnin KA, Bronstein IB, Gaffney DK and
Holden JA: Elevations of DNA topoisomerase I in transitional cell
carcinoma of the urinary bladder: correlation with DNA
topoisomerase II-alpha and p53 expression. Hum Pathol. 30:384–391.
1999.
|
|
12
|
Coleman LW, Perkins SL, Bronstein IB and
Holden JA: Expression of DNA toposiomerase I and DNA topoisomerase
II-alpha in testicular seminomas. Hum Pathol. 31:728–733. 2000.
|
|
13
|
Rody A, Karn T, Ruckhäberle E, Müller V,
Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U and Kaufmann M:
Gene expression of topoisomerase II alpha (TOP2A) by microarray
analysis is highly prognostic in estrogen receptor (ER) positive
breast cancer. Breast Cancer Res Treat. 113:457–466. 2009.
|
|
14
|
Gao XH, Yu ZQ, Zhang C, Bai CG, Zheng JM
and Fu CG: DNA topoisomerase II alpha: a favorable prognostic
factor in colorectal caner. Int J Colorectal Dis. 27:429–435.
2012.
|
|
15
|
Durbecq V, Paesmans M, Cardoso F, Desmedt
C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E,
et al: Topoisomerase-II alpha expression as a predictive marker in
a population of advanced breast cancer patients randomly treated
either with single-agent doxorubicin or single-agent docetaxel. Mol
Cancer Ther. 3:1207–1214. 2004.
|
|
16
|
Lv NL and Kong WM: Expression of
multi-drug resistance genes in cervical cancer and its relationship
with the effect of concurrent radio-chemotherapy. Zhong Liu Xue Za
Zhi. 5:385–388. 2006.(In Chinese).
|
|
17
|
Hicks DG and Tubbs RR: Assessment of the
HER2 status in breast cancer by fluorescence in situ hybridization:
a technical review with interpretive guidelines. Hum Pathol.
36:250–261. 2005.
|
|
18
|
Wong SW, Rangan AM, Bilous AM, Boyages J,
Gebski V and Benson EM: The value of S-phase and DNA ploidy
analysis as prognostic markers for node-negative breast cancer in
the Australian setting. Pathology. 31:90–94. 1999.
|
|
19
|
Horibe Y, Murakami M, Komori K, Imaeda Y
and Kasahara M: Expression of topoisomerase II alpha, Ki-67 and p53
in early stage laryngeal carcinomas not featuring vocal cord
fixation. APMIS. 108:689–696. 2000.
|
|
20
|
Shvero J, Koren R, Shvili I, Yaniv E,
Sadov R and Hadar T: Expression of human DNA Topoisomerase II-alpha
in squamous cell carcinoma of the larynx and its correlation with
clinicopathologic variables. Am J Clin Pathol. 130:934–939.
2008.
|
|
21
|
Deng G, Yang C and Chen W: The expression
of Ki-67 and topoIIalpha in laryngeal squamous cell carcinoma. Lin
Chuang Er Bi Yan Hou Ke Za Zhi. 19:396–398. 2005.(In Chinese).
|
|
22
|
Guo YQ: Mdm2 PARP ToPoII in laryngeal
carcinoma and its clinical significance. Zhong Guo Yi Yao Dao Kan.
1:112–114. 2011.(In Chinese).
|
